Zolbetuximab is named as an intervention in 8 current clinical trials in our USA, China, UK, Ireland and India registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Astellas Pharma Global Development, Inc (6). The most-studied condition is Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer
|
Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | UK, USA, China |
|
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
|
Phase 3 | Recruiting | AstraZeneca | UK, USA, India, China |
|
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
NCT06468280 · ClinicalTrials.gov ↗ · Gastric Cancer, GastroEsophageal Cancer
|
Phase 2 | Recruiting | Shanghai Zhongshan Hospital | China |
|
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer
|
Phase 3 | Active, closed | Astellas Pharma Global Development, Inc. | UK, USA, China |
|
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer
|
Phase 3 | Active, closed | Astellas Pharma Global Development, Inc. | Ireland, UK, USA, China |
|
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320 · ClinicalTrials.gov ↗ · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer
|
Phase 2 | Active, closed | Astellas Pharma Global Development, Inc. | USA |
|
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | Active, closed | Astellas Pharma Global Development, Inc. | Ireland, USA, China |
|
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
NCT06396091 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma
|
Phase 1 | Active, closed | Astellas Pharma Global Development, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Zolbetuximab on the HPRA medicines list.
No entry for Zolbetuximab in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | 3 |
| Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | 3 |
| Metastatic Gastric Adenocarcinoma or Cancer | 3 |
| Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 3 |
| Gastric Cancer | 3 |
| Metastatic Pancreatic Adenocarcinoma | 2 |
| Pancreatic Cancer | 1 |
| Metastatic Pancreatic Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| Pharmacokinetics of Zolbetuximab | 1 |
| Gastro-esophageal Junction (GEJ) Cancer | 1 |
| Pharmacokinetics of Oxaliplatin | 1 |
| GastroEsophageal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 6 |
| AstraZeneca | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 7 | 2 |
| Clinical trials in China | 6 | 3 |
| Clinical trials in UK | 4 | 2 |
| Clinical trials in Ireland | 2 | 0 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
8 current trials in our USA, China, UK, Ireland and India registers name Zolbetuximab as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 8 trials are recruiting: 2 with sites in USA, 3 with sites in China, 2 with sites in UK and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Astellas Pharma Global Development, Inc (6), AstraZeneca (1) and Shanghai Zhongshan Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Zolbetuximab, for example Vyloy 100 mg powder for concentrate for solution for infusion. (Astellas Pharma Europe B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Zolbetuximab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zolbetuximab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zolbetuximab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zolbetuximab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.